Project description
Recombinant antibodies in the treatment of celiac disease
Autoimmune celiac disease is triggered by gluten intake and causes intestinal villi atrophy, resulting in a deficient absorption of nutrients. Primary sources of gluten are wheat, rye, barley and certain oats. At present, a gluten-free diet constitutes the only effective treatment, necessarily excluding consumption of wheat, rye, barley, and oats, which is difficult to achieve. Preliminary data revealed that an antibody against the most immunogenic gluten peptide suppresses 90 % of hydrolysed gluten immunogenicity ex vivo. The EU-funded GIPTRAP project aims to develop a new therapeutic strategy to overcome the effect of exposure to gluten in celiac patients. The objective is to assess the potential of anti-gluten immunogenic peptides antibodies as therapeutic tools, evaluating their effectiveness in vitro and ex vivo.
Objective
Celiac disease affects about 1% of the population worldwide. It is an autoimmune disease triggered by gluten intake in genetically predisposed individuals. Celiac disease causes intestinal villi atrophy that results in a deficient absorption of nutrients and other risks. Gluten major sources are wheat, rye, barley and some oats. Currently, the only effective treatment is a permanent gluten free diet (GFD). However, a fully GFD is difficult to achieve. The average daily gluten intake in celiac patients is estimated to be 150-400 mg, when 50 mg are enough to damage the intestine of most celiac patients. Accordingly, symptoms persist in 65% of patients, with only 8% reaching complete gut recovery. Preliminary data showed that an antibody raised against the most immunogenic gluten peptide suppressed 90% immunogenicity of hydrolyzed gluten ex vivo. This project proposes a novel therapeutic strategy to alleviate the effect of exposure to gluten for celiac patients not completely responsive to GFD. I aim to assess the potential of anti-Gluten Immunogenic Peptides (GIP) antibodies as therapeutic tools by evaluating their effectiveness to neutralize GIP in vitro and ex vivo. I will develop improved humanized recombinant versions of anti-GIP antibodies, analyze their performance and stability, and optimize their production in mammalian cell cultures in collaboration with partner biotech companies and academia research groups with long experience in the field, bringing novel transferable knowledge to the host institution. The recombinant antibodies will also be explored for their improved performance in diagnostic applications for determining GIP excretion. This Fellowship will allow to extend my existing network beyond Academia towards Biotech Industry and will provide me with significant experience to mature towards independent project management in industrial research in the fields of recombinant protein production and immunotherapy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology autoimmune diseases
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine gastroenterology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
41900 Camas/Sevilla
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.